Unit:
Oncology
Presenters:
Dr Prudence Scott
Topic: “Are Phase 3 trials
obsolete?”
Rationally
designed targeted therapies to treat cancer have led to unprecedented
improvements in treatment outcomes compared with existing standards of care.
The resulting demand for earlier access from patients, clinicians and the
pharmaceutical industry has led to a paradigm shift in clinical trial design
and the evidence required for regulatory approval of medicines.
This has
brought challenges and opportunities, and these will be presented, both from a
global and Australian perspective, based on what was learnt during nearly 3
years as Director of the Oncology/Haematology Evaluation Unit at the
Therapeutic Goods Administration.
Date:
Wednesday 2 November 2016
Time: 12.30pm to 1.30pm
Venue: Main Lecture
Theatre, Monash Medical Centre, Clayton.
No comments:
Post a Comment